President Trump has announced that Medicare will cover GLP-1 weight loss drugs, including Ozempic, Zepbound, and Wegovy, at $50 (£40) per month starting 1 July. These drugs, which have revolutionised weight management, will become accessible to millions of seniors for a fraction of their current market cost.
Previously, these treatments were often excluded from basic coverage, leaving many to pay thousands out of pocket. This policy change marks one of the most substantial expansions of government-funded pharmaceutical access in recent years.
